Sunesis Pharmaceuticals (SNSS) stock price, revenue, and financials

Sunesis Pharmaceuticals market cap is $96.3 m, and annual revenue was $120 k in FY 2020

$96.3 M

SNSS Mkt cap, 26-Feb-2021

$120 K

Sunesis Pharmaceuticals Revenue FY, 2020
Sunesis Pharmaceuticals Net income (FY, 2020)-21.6 M
Sunesis Pharmaceuticals EBIT (FY, 2020)-22.3 M
Sunesis Pharmaceuticals Cash, 31-Dec-202020.4 M
Sunesis Pharmaceuticals EV76.5 M
Get notified regarding key financial metrics and revenue changes at Sunesis PharmaceuticalsLearn more
Banner background

Sunesis Pharmaceuticals Income Statement

Sunesis Pharmaceuticals Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

7.6m11.9m5.3m11.7m41.6m12.6m6.6m21.7m50.4m26.8m20.8m18.8m20.3m16.8m23.9m9.4m5.8m11.5m11.7m7.9m21.4m17.0m20.2m24.8m9.8m19.7m20.0m17.7m26.0m

Prepaid Expenses

1.4m1.8m1.9m1.6m1.7m1.2m998.0k1.0m1.1m1.1m1.3m1.5m1.2m796.0k701.0k831.0k840.0k714.0k840.0k1.3m1.5m1.5m1.3m1.6m2.2m2.2m1.8m1.7m1.6m

Current Assets

50.3m43.5m36.7m30.9m78.2m62.2m50.6m46.5m71.8m59.7m46.0m41.3m40.7m31.3m40.7m34.0m25.1m35.9m23.5m13.7m26.9m21.9m21.5m26.4m19.8m40.5m30.7m24.9m27.6m

PP&E

94.0k82.0k66.0k58.0k50.0k36.0k31.0k27.0k41.0k35.0k53.0k31.0k19.0k17.0k11.0k8.0k6.0k1.0k25.0k22.0k18.0k16.0k14.0k9.0k7.0k5.0k1.0k

Total Assets

50.4m43.7m36.9m31.0m78.4m62.3m50.6m46.6m71.8m59.7m46.1m41.3m40.7m31.3m40.7m34.0m25.1m35.9m24.9m15.1m27.0m22.0m21.6m27.8m21.0m41.6m31.5m25.5m28.0m

Accounts Payable

329.0k327.0k869.0k393.0k1.2m1.5m2.1m1.5m1.0m513.0k772.0k2.1m2.3m1.8m2.6m2.8m2.5m2.6m2.3m1.5m1.0m1.6m1.3m861.0k692.0k770.0k862.0k452.0k150.0k

Short-term debt

50.0k900.0k4.4m8.2m8.5m8.8m9.3m9.6m9.9m713.0k3.3m5.9m833.0k2.1m4.6m1.7m2.5m7.3m7.3m7.3m6.6m6.0m6.0m6.0m6.0m409.0k

Current Liabilities

10.1m7.8m12.7m15.2m35.1m35.9m35.2m35.3m37.7m39.6m37.3m15.9m18.3m16.1m9.8m10.4m10.5m11.4m7.0m7.4m11.6m12.0m12.3m10.0m8.7m8.9m9.3m9.4m3.6m

Long-term debt

9.5m8.7m19.6m15.6m22.0m11.3m6.7m4.2m1.7m6.9m4.4m1.9m11.7m13.4m12.3m9.9m5.4m4.7m1.9m1.6m1.4m817.0k545.0k409.0k

Total Debt

9.5m9.6m24.0m23.8m30.5m20.0m16.0m13.8m11.6m7.6m7.7m7.8m11.7m14.3m14.4m14.5m7.1m7.2m14.5m14.6m14.7m12.1m10.9m10.9m6.8m6.6m818.0k

Total Liabilities

12.3m10.7m9.3m9.3m9.4m9.4m3.6m

Common Stock

5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k6.0k6.0k6.0k7.0k7.0k8.0k9.0k9.0k1.0k2.0k2.0k2.0k3.0k4.0k4.0k7.0k7.0k11.0k11.0k11.0k2.0k

Preferred Stock

16.5m16.5m16.5m18.8m18.8m16.5m21.0m21.0m21.0m25.6m7.1m11.8m11.8m11.8m5.5m

Additional Paid-in Capital

427.7m428.2m429.7m430.7m451.0m457.8m459.1m466.7m520.0m521.9m525.0m548.6m558.0m559.8m572.3m573.5m574.6m602.8m609.7m612.6m634.5m636.0m641.8m656.8m676.2m698.0m698.9m699.3m718.5m

Retained Earnings

(387.4m)(392.4m)(415.1m)(423.6m)(441.0m)(456.7m)(464.9m)(472.5m)(494.3m)(506.0m)(521.4m)(531.8m)(540.8m)(547.8m)(569.5m)(579.9m)(588.9m)(607.2m)(616.1m)(626.2m)(640.1m)(647.0m)(653.5m)(665.3m)(671.6m)(677.5m)(688.6m)(695.0m)(699.6m)

Total Equity

40.3m35.8m14.7m7.1m10.0m1.1m(5.8m)(5.8m)25.8m15.8m3.6m16.8m17.2m12.1m19.3m10.1m2.2m14.3m12.5m2.9m15.4m10.0m9.3m17.1m11.7m32.3m22.1m16.1m24.5m

Debt to Equity Ratio

0.7 x1.4 x2.4 x21.6 x-5.3 x-3.5 x0.6 x0.9 x3.2 x0.5 x0.4 x0.6 x0.6 x1.4 x6.5 x1 x0.6 x2.5 x0.9 x1.5 x1.6 x0.7 x0.9 x0.3 x0.3 x0.4 x

Debt to Assets Ratio

0.3 x0.3 x0.3 x0.4 x0.6 x0.4 x0.2 x0.2 x0.3 x0.2 x0.2 x0.2 x0.3 x0.4 x0.6 x0.4 x0.3 x0.5 x0.5 x0.7 x0.7 x0.4 x0.5 x0.3 x0.2 x0.3 x

Financial Leverage

1.3 x1.2 x2.5 x4.4 x7.9 x56.4 x-8.8 x-8.1 x2.8 x3.8 x12.7 x2.5 x2.4 x2.6 x2.1 x3.4 x11.4 x2.5 x2 x5.2 x1.8 x2.2 x2.3 x1.6 x1.8 x1.3 x1.4 x1.6 x1.1 x

Sunesis Pharmaceuticals Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(6.4m)(11.4m)(13.9m)(22.5m)(39.9m)(11.6m)(19.8m)(27.4m)(14.6m)(26.4m)(41.7m)(9.1m)(18.1m)(25.1m)(10.1m)(20.5m)(29.5m)(9.8m)(18.7m)(28.8m)(7.3m)(14.1m)(20.6m)(5.9m)(12.1m)(18.0m)(5.8m)(12.2m)(16.8m)

Depreciation and Amortization

38.0k47.0k8.0k16.0k24.0k7.0k12.0k16.0k5.0k11.0k18.0k11.0k22.0k24.0k3.0k6.0k8.0k2.0k4.0k7.0k2.0k4.0k6.0k2.0k4.0k6.0k(37.0k)(41.0k)(41.0k)

Accounts Receivable

Accounts Payable

(87.0k)(89.0k)211.0k(265.0k)529.0k1.4m2.0m1.4m58.0k(440.0k)(181.0k)(1.1m)(895.0k)(1.4m)128.0k306.0k73.0k776.0k406.0k(330.0k)(659.0k)(144.0k)(420.0k)(532.0k)(701.0k)(623.0k)71.0k(339.0k)(641.0k)

Cash From Operating Activities

(8.9m)(15.6m)(9.3m)(15.1m)(1.4m)(9.5m)(19.0m)(27.7m)(11.4m)(21.6m)(34.2m)(11.6m)(19.8m)(29.5m)(10.7m)(20.1m)(29.0m)(9.7m)(20.5m)(30.8m)(6.5m)(12.4m)(17.9m)(6.1m)(13.0m)(18.4m)(5.7m)(11.5m)(15.8m)

Purchases of PP&E

(16.0k)(15.0k)(23.0k)(23.0k)(48.0k)(26.0k)(26.0k)

Cash From Investing Activities

(1.8m)9.2m5.2m17.1m(181.0k)7.8m13.3m32.7m3.9m(7.6m)206.0k(212.0k)1.5m7.1m3.4m(4.1m)1.1m10.8m23.5m30.0m742.0k1.4m4.8m(2.4m)(13.1m)13.0m16.4m16.4m

Short-term Borrowings

(694.0k)(2.8m)(5.0m)(2.3m)(4.6m)(6.9m)(1.6m)(1.6m)(1.6m)(830.0k)(830.0k)(830.0k)(7.5m)(7.6m)(1.4m)(7.5m)(7.5m)(5.5m)

Cash From Financing Activities

4.1m4.1m32.0k461.0k33.9m(653.0k)(2.6m)1.8m42.8m40.9m39.6m8.4m16.4m17.0m4.3m6.8m6.8m2.2m574.0k656.0k196.0k1.1m6.3m17.2m17.0m43.1m23.0k7.2m

Net Change in Cash

(6.6m)(2.3m)(4.0m)2.4m32.3m(2.4m)(8.3m)6.8m35.2m11.6m5.7m(3.4m)(1.9m)(5.4m)(3.0m)(17.4m)(21.1m)3.4m3.6m(109.0k)(5.6m)(9.9m)(6.8m)11.1m1.6m11.5m7.2m4.9m7.8m

Sunesis Pharmaceuticals Ratios

USDQ2, 2011

Financial Leverage

1.3 x

Sunesis Pharmaceuticals Employee Rating

4.26 votes
Culture & Values
5
Work/Life Balance
4.5
Senior Management
4.4
Salary & Benefits
3.5
Career Opportunities
3.4
Source